Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

ABSTRACT:

SUBMITTER: Roviello G 

PROVIDER: S-EPMC8273868 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature